Brokerages forecast that Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) will announce $523.38 million in sales for the current quarter, according to Zacks Investment Research. Nine analysts have provided estimates for Allscripts Healthcare Solutions’ earnings. The lowest sales estimate is $520.60 million and the highest is $526.90 million. Allscripts Healthcare Solutions reported sales of $429.40 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 21.9%. The company is expected to issue its next quarterly earnings report after the market closes on Thursday, February 15th.

According to Zacks, analysts expect that Allscripts Healthcare Solutions will report full year sales of $523.38 million for the current year, with estimates ranging from $1.81 billion to $1.82 billion. For the next fiscal year, analysts anticipate that the company will post sales of $2.14 billion per share, with estimates ranging from $2.11 billion to $2.18 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that cover Allscripts Healthcare Solutions.

Several research firms have recently weighed in on MDRX. Robert W. Baird lifted their price objective on Allscripts Healthcare Solutions from $16.00 to $17.00 and gave the company an “outperform” rating in a research note on Friday, November 3rd. KeyCorp reaffirmed a “hold” rating on shares of Allscripts Healthcare Solutions in a research note on Friday, October 27th. Zacks Investment Research lowered Allscripts Healthcare Solutions from a “buy” rating to a “hold” rating in a research note on Wednesday, November 8th. BidaskClub raised Allscripts Healthcare Solutions from a “hold” rating to a “buy” rating in a research note on Wednesday, December 20th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Allscripts Healthcare Solutions in a research note on Wednesday, September 27th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and twelve have given a buy rating to the company. Allscripts Healthcare Solutions has an average rating of “Buy” and a consensus price target of $14.94.

In related news, SVP James Hewitt sold 36,796 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $14.11, for a total transaction of $519,191.56. Following the transaction, the senior vice president now directly owns 181,766 shares of the company’s stock, valued at approximately $2,564,718.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, President Richard J. Poulton sold 15,000 shares of Allscripts Healthcare Solutions stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $14.26, for a total value of $213,900.00. Following the sale, the president now owns 1,351,773 shares in the company, valued at $19,276,282.98. The disclosure for this sale can be found here. Insiders have sold a total of 56,796 shares of company stock worth $804,842 over the last three months. 0.75% of the stock is currently owned by corporate insiders.

Hedge funds have recently bought and sold shares of the business. Fuller & Thaler Asset Management Inc. increased its holdings in Allscripts Healthcare Solutions by 1.0% during the 3rd quarter. Fuller & Thaler Asset Management Inc. now owns 5,062,035 shares of the software maker’s stock worth $72,033,000 after purchasing an additional 49,823 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Allscripts Healthcare Solutions by 26.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 9,171,285 shares of the software maker’s stock worth $117,026,000 after purchasing an additional 1,943,496 shares during the last quarter. Royal Bank of Canada increased its holdings in Allscripts Healthcare Solutions by 53.3% during the 2nd quarter. Royal Bank of Canada now owns 955,183 shares of the software maker’s stock worth $12,189,000 after purchasing an additional 331,967 shares during the last quarter. Vanguard Group Inc. increased its holdings in Allscripts Healthcare Solutions by 1.2% during the 2nd quarter. Vanguard Group Inc. now owns 14,824,640 shares of the software maker’s stock worth $189,162,000 after purchasing an additional 181,721 shares during the last quarter. Finally, Ameritas Investment Partners Inc. increased its holdings in Allscripts Healthcare Solutions by 30.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 69,163 shares of the software maker’s stock worth $883,000 after purchasing an additional 15,950 shares during the last quarter.

Allscripts Healthcare Solutions (NASDAQ MDRX) traded up $0.17 during midday trading on Friday, hitting $15.35. The stock had a trading volume of 1,855,516 shares, compared to its average volume of 2,293,815. The firm has a market cap of $2,773.45, a price-to-earnings ratio of -13.23, a P/E/G ratio of 2.17 and a beta of 1.33. Allscripts Healthcare Solutions has a fifty-two week low of $10.24 and a fifty-two week high of $15.40. The company has a quick ratio of 0.98, a current ratio of 0.98 and a debt-to-equity ratio of 1.20.

COPYRIGHT VIOLATION WARNING: This article was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.watchlistnews.com/523-38-million-in-sales-expected-for-allscripts-healthcare-solutions-inc-mdrx-this-quarter/1797962.html.

Allscripts Healthcare Solutions Company Profile

Allscripts Healthcare Solutions, Inc (Allscripts) delivers information technology (IT) solutions and services to help healthcare organizations. The Company operates through three segments: Clinical and Financial Solutions, Population Health, and Netsmart. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions.

Get a free copy of the Zacks research report on Allscripts Healthcare Solutions (MDRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Allscripts Healthcare Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions and related companies with Analyst Ratings Network's FREE daily email newsletter.